100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44HL150923
Award Date
5/1/20
Completion Date
4/30/23
Dollars Obligated
$3.8M
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Shifa Biomedical Corporation (J3TLJQ7LFK49)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Malvern, PA 19355, USA
Update #1
Update #2
ORAL PCSK9/LDLR ANTAGONIST DIRECTION TO THE CLINIC
Posted 4/24/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
ORAL PCSK9/LDLR ANTAGONIST DIRECTION TO THE CLINIC - PROJECT SUMMARY/ABSTRACT HEART DISEASE HAS BEEN THE LEADING CAUSE OF DEATH IN THE UNITED STATES AND THE WORLD FOR MORE THAN A CENTURY, EVER SINCE THE EARLY 1900S. ABOUT 610,000 PEOPLE DIE OF HEART DISEASE IN THE UNITED STATES EVERY YEAR-THAT'S 1 IN EVERY 4 DEATHS. THE EPIDEMIC BURDEN IS ENORMOUS; IN 2016, CARDIOVASCULAR DISEASE (CVD) COST $555 BILLION IN THE US ALONE, AND BY 2035, THE COST WILL SKYROCKET TO $1.1 TRILLION. A HIGH CHOLESTEROL LEVEL IS WELL-KNOWN RISK FACTORS FOR HEART DISEASE. ALTHOUGH BLOOD CHOLESTEROL CAN BE LOWERED USING A NUMBER OF MARKETED DRUGS, OF WHICH STATINS ARE THE LEADING DRUGS, MORE THAN 7M PATIENTS HAVE HIGH LDL-CHOLESTEROL AND NOT RESPONSIVE TO STATIN, AND AN ADDITIONAL 4M STATIN INTOLERANCE AND 1.3M ARE FAMILIAL HYPERCHOLESTEREMIC (FH). THESE AND OTHER PATIENTS WILL DRAMATICALLY BENEFIT FROM AN AGGRESSIVE TREATMENT OF HYPERCHOLESTEROLEMIA. THE LONG-TERM GOAL OF THIS WORK IS TO DEVELOP NOVEL ORALLY BIOAVAILABLE DRUGS FOR CHOLESTEROL LOWERING. OUR THERAPEUTIC TARGET IS THE PROTEASE PROPROTEIN CONVERTASE SUBTILISIN-LIKE KEXIN TYPE 9 (PCSK9). PCSK9 CONTROLS THE DEGRADATION OF THE LDL RECEPTOR (LDLR) IN THE LIVER AND THEREBY CONTRIBUTES TO CHOLESTEROL HOMEOSTASIS. PCSK9 IS SYNTHESIZED AS A PRECURSOR PROTEIN THAT UNDERGOES PROCESSING. SECRETED PCSK9 BINDS TO THE LDL-RECEPTOR (LDLR) AND CHAPERONES IT TO THE DEGRADATION PATHWAY. TO ACHIEVE OUR GOAL, WE IDENTIFIED A NANOMOLAR ORALLY ACTIVE SMALL MOLECULE PCSK9/LDLR ANTAGONIST (P-21) THAT SHOWED OUTSTANDING POTENCY IN MICE FED HIGH-FAT DIET. THE LDL- CHOLESTEROL LOWERING EFFECT OF P-21 IS AS POTENT AS THE MARKETED MONOCLONAL ANTIBODIES. AS PART OF THIS PHASE-II SBIR PROPOSAL, OUR GOAL IS TO ADVANCE THE DEVELOPMENT OF OUR LEAD COMPOUND (P-21) TO PHASE-I CLINICAL TRIAL. OUR STUDIES WILL FOCUS ON ENSURING THAT P-21 ADHERES TO THE SET OF ESTABLISHED CRITERIA AS A PRE-CLINICAL CANDIDATE AND ON UNDERTAKING THE WORK REQUIRED TO OBTAIN THE SAFETY AND TOXICOLOGY STUDIES IN TWO MAMMALIAN SPECIES REQUIRED FOR A GLP-IND ENABLING STUDY APPLICATION SUBMISSION.
$0
12/28/23
Not listed
ORAL PCSK9/LDLR ANTAGONIST DIRECTION TO THE CLINIC - PROJECT SUMMARY/ABSTRACT HEART DISEASE HAS BEEN THE LEADING CAUSE OF DEATH IN THE UNITED STATES AND THE WORLD FOR MORE THAN A CENTURY, EVER SINCE THE EARLY 1900S. ABOUT 610,000 PEOPLE DIE OF HEART DISEASE IN THE UNITED STATES EVERY YEAR-THAT'S 1 IN EVERY 4 DEATHS. THE EPIDEMIC BURDEN IS ENORMOUS; IN 2016, CARDIOVASCULAR DISEASE (CVD) COST $555 BILLION IN THE US ALONE, AND BY 2035, THE COST WILL SKYROCKET TO $1.1 TRILLION. A HIGH CHOLESTEROL LEVEL IS WELL-KNOWN RISK FACTORS FOR HEART DISEASE. ALTHOUGH BLOOD CHOLESTEROL CAN BE LOWERED USING A NUMBER OF MARKETED DRUGS, OF WHICH STATINS ARE THE LEADING DRUGS, MORE THAN 7M PATIENTS HAVE HIGH LDL-CHOLESTEROL AND NOT RESPONSIVE TO STATIN, AND AN ADDITIONAL 4M STATIN INTOLERANCE AND 1.3M ARE FAMILIAL HYPERCHOLESTEREMIC (FH). THESE AND OTHER PATIENTS WILL DRAMATICALLY BENEFIT FROM AN AGGRESSIVE TREATMENT OF HYPERCHOLESTEROLEMIA. THE LONG-TERM GOAL OF THIS WORK IS TO DEVELOP NOVEL ORALLY BIOAVAILABLE DRUGS FOR CHOLESTEROL LOWERING. OUR THERAPEUTIC TARGET IS THE PROTEASE PROPROTEIN CONVERTASE SUBTILISIN-LIKE KEXIN TYPE 9 (PCSK9). PCSK9 CONTROLS THE DEGRADATION OF THE LDL RECEPTOR (LDLR) IN THE LIVER AND THEREBY CONTRIBUTES TO CHOLESTEROL HOMEOSTASIS. PCSK9 IS SYNTHESIZED AS A PRECURSOR PROTEIN THAT UNDERGOES PROCESSING. SECRETED PCSK9 BINDS TO THE LDL-RECEPTOR (LDLR) AND CHAPERONES IT TO THE DEGRADATION PATHWAY. TO ACHIEVE OUR GOAL, WE IDENTIFIED A NANOMOLAR ORALLY ACTIVE SMALL MOLECULE PCSK9/LDLR ANTAGONIST (P-21) THAT SHOWED OUTSTANDING POTENCY IN MICE FED HIGH-FAT DIET. THE LDL- CHOLESTEROL LOWERING EFFECT OF P-21 IS AS POTENT AS THE MARKETED MONOCLONAL ANTIBODIES. AS PART OF THIS PHASE-II SBIR PROPOSAL, OUR GOAL IS TO ADVANCE THE DEVELOPMENT OF OUR LEAD COMPOUND (P-21) TO PHASE-I CLINICAL TRIAL. OUR STUDIES WILL FOCUS ON ENSURING THAT P-21 ADHERES TO THE SET OF ESTABLISHED CRITERIA AS A PRE-CLINICAL CANDIDATE AND ON UNDERTAKING THE WORK REQUIRED TO OBTAIN THE SAFETY AND TOXICOLOGY STUDIES IN TWO MAMMALIAN SPECIES REQUIRED FOR A GLP-IND ENABLING STUDY APPLICATION SUBMISSION.
$945.4k
4/20/21
Not listed
ORAL PCSK9/LDLR ANTAGONIST DIRECTION TO THE CLINIC - PROJECT SUMMARY/ABSTRACT HEART DISEASE HAS BEEN THE LEADING CAUSE OF DEATH IN THE UNITED STATES AND THE WORLD FOR MORE THAN A CENTURY, EVER SINCE THE EARLY 1900S. ABOUT 610,000 PEOPLE DIE OF HEART DISEASE IN THE UNITED STATES EVERY YEAR-THAT'S 1 IN EVERY 4 DEATHS. THE EPIDEMIC BURDEN IS ENORMOUS; IN 2016, CARDIOVASCULAR DISEASE (CVD) COST $555 BILLION IN THE US ALONE, AND BY 2035, THE COST WILL SKYROCKET TO $1.1 TRILLION. A HIGH CHOLESTEROL LEVEL IS WELL-KNOWN RISK FACTORS FOR HEART DISEASE. ALTHOUGH BLOOD CHOLESTEROL CAN BE LOWERED USING A NUMBER OF MARKETED DRUGS, OF WHICH STATINS ARE THE LEADING DRUGS, MORE THAN 7M PATIENTS HAVE HIGH LDL-CHOLESTEROL AND NOT RESPONSIVE TO STATIN, AND AN ADDITIONAL 4M STATIN INTOLERANCE AND 1.3M ARE FAMILIAL HYPERCHOLESTEREMIC (FH). THESE AND OTHER PATIENTS WILL DRAMATICALLY BENEFIT FROM AN AGGRESSIVE TREATMENT OF HYPERCHOLESTEROLEMIA. THE LONG-TERM GOAL OF THIS WORK IS TO DEVELOP NOVEL ORALLY BIOAVAILABLE DRUGS FOR CHOLESTEROL LOWERING. OUR THERAPEUTIC TARGET IS THE PROTEASE PROPROTEIN CONVERTASE SUBTILISIN-LIKE KEXIN TYPE 9 (PCSK9). PCSK9 CONTROLS THE DEGRADATION OF THE LDL RECEPTOR (LDLR) IN THE LIVER AND THEREBY CONTRIBUTES TO CHOLESTEROL HOMEOSTASIS. PCSK9 IS SYNTHESIZED AS A PRECURSOR PROTEIN THAT UNDERGOES PROCESSING. SECRETED PCSK9 BINDS TO THE LDL-RECEPTOR (LDLR) AND CHAPERONES IT TO THE DEGRADATION PATHWAY. TO ACHIEVE OUR GOAL, WE IDENTIFIED A NANOMOLAR ORALLY ACTIVE SMALL MOLECULE PCSK9/LDLR ANTAGONIST (P-21) THAT SHOWED OUTSTANDING POTENCY IN MICE FED HIGH-FAT DIET. THE LDL- CHOLESTEROL LOWERING EFFECT OF P-21 IS AS POTENT AS THE MARKETED MONOCLONAL ANTIBODIES. AS PART OF THIS PHASE-II SBIR PROPOSAL, OUR GOAL IS TO ADVANCE THE DEVELOPMENT OF OUR LEAD COMPOUND (P-21) TO PHASE-I CLINICAL TRIAL. OUR STUDIES WILL FOCUS ON ENSURING THAT P-21 ADHERES TO THE SET OF ESTABLISHED CRITERIA AS A PRE-CLINICAL CANDIDATE AND ON UNDERTAKING THE WORK REQUIRED TO OBTAIN THE SAFETY AND TOXICOLOGY STUDIES IN TWO MAMMALIAN SPECIES REQUIRED FOR A GLP-IND ENABLING STUDY APPLICATION SUBMISSION.
$945.4k
4/20/21
Not listed
ORAL PCSK9/LDLR ANTAGONIST DIRECTION TO THE CLINIC
$943.9k
4/24/20